Focused On-demand Library for C-type lectin domain family 4 member M

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9H2X3

UPID:

CLC4M_HUMAN

Alternative names:

CD209 antigen-like protein 1; DC-SIGN-related protein; Dendritic cell-specific ICAM-3-grabbing non-integrin 2; Liver/lymph node-specific ICAM-3-grabbing non-integrin

Alternative UPACC:

Q9H2X3; A6NKI4; A8K8B3; Q69F40; Q969M4; Q96QP3; Q96QP4; Q96QP5; Q96QP6; Q9BXS3; Q9H2Q9; Q9H8F0; Q9Y2A8

Background:

C-type lectin domain family 4 member M, known as CD209 antigen-like protein 1, plays a crucial role in immune surveillance, particularly in the liver. It mediates endocytosis of pathogens for degradation and serves as a receptor for ICAM3. Its ability to bind to mannose-like carbohydrates facilitates the recognition of various pathogens, including Ebolavirus, Hepatitis C virus, HIV-1, and several coronaviruses.

Therapeutic significance:

Understanding the role of C-type lectin domain family 4 member M could open doors to potential therapeutic strategies. Its involvement in the recognition and endocytosis of a wide range of pathogens highlights its potential as a target for developing treatments against infectious diseases.